GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (STU:56R0) » Definitions » Forward PE Ratio

NanoVibronix (STU:56R0) Forward PE Ratio : 0.00 (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NanoVibronix Forward PE Ratio?

NanoVibronix's Forward PE Ratio for today is 0.00.

NanoVibronix's PE Ratio without NRI for today is 0.00.

NanoVibronix's PE Ratio for today is 0.00.


NanoVibronix Forward PE Ratio Historical Data

The historical data trend for NanoVibronix's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoVibronix Forward PE Ratio Chart

NanoVibronix Annual Data
Trend
Forward PE Ratio

NanoVibronix Quarterly Data
Forward PE Ratio

Competitive Comparison of NanoVibronix's Forward PE Ratio

For the Medical Devices subindustry, NanoVibronix's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoVibronix's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoVibronix's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where NanoVibronix's Forward PE Ratio falls into.



NanoVibronix Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


NanoVibronix  (STU:56R0) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


NanoVibronix Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of NanoVibronix's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoVibronix (STU:56R0) Business Description

Traded in Other Exchanges
Address
525 Executive Boulevard, Elmsford, New York, NY, USA, 10523
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

NanoVibronix (STU:56R0) Headlines

No Headlines